BIIB — BIOGEN INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 875045 ·
Last close
$202.95
Market Cap
$29.99B
52W High
$219.72
52W Low
$184.90
ADV30
1,451,331
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 2,477,800,000 | 1,816,800,000 | 459,800,000 | 319,500,000 | 29,483,100,000 | 3,382,700,000 | 10,831,400,000 |
| Dec 2025 | 2,279,400,000 | 1,783,900,000 | 385,500,000 | -48,900,000 | 29,439,500,000 | 3,008,500,000 | 11,182,700,000 |
| Sep 2025 | 2,534,700,000 | 1,860,300,000 | 606,500,000 | 466,500,000 | 29,207,500,000 | 3,862,800,000 | 11,000,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,590,800,000
Investing CF
$-1,533,300,000
Financing CF
$-322,700,000
CapEx
$-274,500,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$9.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$20,872,200,000
Inventory
$1,949,000,000
Receivables
$1,790,400,000
ST Investments
$900,000,000
EBIT TTM
$1,898,100,000
Pretax Income TTM
$1,623,000,000
Interest Exp TTM
$275,100,000
Analysts
29
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,027,899,904
EBITDA
$3,359,200,000
Free Cash Flow
$1,266,987,520
Enterprise Value
$37,792,587,776
Total Cash
$1,284,999,936
Total Debt
$8,355,100,160
Shares Out
147,753,998
Trailing EPS
$5.59
Book Value
$124.36
ROE
4.6%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,890,600,000 | 2,469,000,000 | 1,292,900,000 | 29,439,500,000 | 11,182,700,000 | — | 2,204,600,000 |
| Dec 2024 | 9,675,900,000 | 2,280,400,000 | 1,632,200,000 | 28,049,300,000 | 11,333,300,000 | — | 2,875,500,000 |
| Dec 2023 | 9,835,600,000 | 1,847,700,000 | 1,161,100,000 | 26,844,800,000 | 12,045,400,000 | — | 1,547,200,000 |
| Dec 2022 | 10,173,400,000 | 2,901,900,000 | 3,046,900,000 | 24,554,100,000 | 11,165,700,000 | — | 1,384,300,000 |
TTM Snapshot
Revenues TTM
$10,283,500,000
NetIncome TTM
$1,784,300,000
OpCashFlow TTM
$0
Assets (Latest)
$28,049,300,000
Forward EPS
$16.58
Max Pain — expiry 2026-09-18
max pain strike: $200.00 · spot: $202.95 · call oi: 4,780 · put oi: 5,305
Expected Move to 2026-09-18:
±$20.30
(10.00%) —
implied range
$182.65 –
$223.25
· ATM straddle on $200.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTX | BioNTech SE | $22.91B | $90.58 | — |
| RVMD | Revolution Medicines, Inc. | $39.87B | $187.53 | — |
| MRNA | Moderna, Inc. | $21.75B | $54.82 | — |
| ARGX | ARGENX SE | $53.42B | $853.82 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.77B | $166.80 | — |
News headlines (Yahoo Finance, 1h cache)
Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?
2026-07-31 19:29 · Yahoo
Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?
2026-07-30 06:08 · Yahoo
Why Biogen Stock Topped the Market Today
2026-07-29 23:43 · Yahoo
Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ...
2026-07-29 21:03 · Yahoo
Biogen Inc. Q2 2026 Earnings Call Summary
2026-07-29 19:31 · Yahoo
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
2026-07-29 17:20 · Yahoo
Why Biogen Stock Is Resisting a Market Downturn After Earnings
2026-07-29 16:21 · Yahoo
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
2026-07-29 15:09 · Yahoo
Biogen Q2 Earnings Call Highlights
2026-07-29 14:04 · Yahoo
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-07-29 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.